Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Horizon Announces Oncology Drug Discovery Collaboration with AstraZeneca

Published: Monday, April 22, 2013
Last Updated: Monday, April 22, 2013
Bookmark and Share
Agreement to explore Horizon’s first-in-class kinase target programme, HD-001.

Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.

The HD-001 program, currently in the early stages of drug discovery, has the potential to be developed into a treatment based on modulation of a novel kinase.

This target has been shown to be mutated in a range of cancer types including colon and lung. Importantly, the target has also been shown to play a key role in K-Ras mutant tumours.

K-Ras is mutated in up to 40% of all cancer types causing resistance to many of the available targeted therapeutics and as a result is associated with poor patient outcomes, which makes the development of molecular targeted therapies against the gene a significant unmet need.

Dr Chris Torrance, CSO and leader of the HD-001 program at Horizon, commented: “Targeting cancer cells harboring mutant K-Ras has been a perennial issue for the drug discovery community, with few canonical pathway or ‘gene-addiction’ targets showing a clear benefit on this important cancer gene. We are excited to partner with Astra Zeneca on the development of HD-001, as they have shown a firm commitment to the identification of novel K-Ras targets.”

Dr Darrin M Disley, CEO at Horizon Discovery, said: “The program has benefitted greatly from the use of Horizon’s drug discovery toolbox to first exquisitely validate the target and then provide a range of ‘on-target’ cellular assays to support rational drug discovery. As a result, the lead discovery effort has been rapid, resulting in a diverse portfolio of potent and selective inhibitors of the target. The novelty of the target combined with the unique suite of biological and chemical tools assembled will provide AstraZeneca with a strong base to launch its pre-clinical and clinical research efforts; supported in the early stages by our own research scientists.”

Susan Galbraith, Head of the Oncology Innovative Medicines Unit at AstraZeneca, said: “Horizon’s novel kinase target programme coupled with their target validation technology allows us to broaden our oncology research efforts beyond our own internal capabilities. AstraZeneca has a proven track record of collaborating on early stage discovery projects with innovative organizations like Horizon, partnering their cutting-edge science with our strong oncology expertise to bring new medicines to cancer patients.”

Under the terms of the agreement, Horizon will receive undisclosed upfront and preclinical milestone payments, and are eligible for clinical and approval milestones totaling up to $75M, as well as tiered royalties.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Horizon In-licenses Oncology Programme from Servier
License programme with milestone payments of up to £50 million plus royalties on product sales.
Thursday, October 08, 2015
Horizon and Redx Sign Cancer Research Collaboration
Collaboration to progress Redx Pharma plc’s novel pan-RAF inhibitor program towards out-licensing.
Friday, September 04, 2015
Horizon to Support Cancer Research UK’s Stratified Medicine Program
Horizon’s Diagnostics division to provide genetically defined, human genomic reference standards.
Friday, March 13, 2015
Horizon Discovery Appoints Dr David Smoller as an Executive Director
Company announces the appointment of Dr David Smoller, Chief Business Officer of Horizon, as an Executive Director of the Board, with immediate effect.
Monday, November 03, 2014
Horizon Signs Master Services Agreement for Approximately $1.2 Million
Agreement covers development of molecular reference standards for companion diagnostics.
Friday, September 26, 2014
Horizon Discovery Adds Three Eminent CRISPR Experts to its SAB
Dr. Emmanuelle Charpentier, Dr. J. Keith Joung, and Dr. Feng Zhang join the Company’s panel of expert gene editing advisors.
Tuesday, August 05, 2014
Horizon and OPDC Sign Collaboration Agreement
Horizon CombinatoRx to perform in-vitro cell line screening of OPDC clinical stage development candidates.
Friday, July 25, 2014
Horizon Licenses AAV Gene Delivery Technology from Stanford University
Agreement supplements existing exclusive rAAV gene targeting license from University of Washington.
Thursday, July 03, 2014
Horizon, LGC Awarded Technology Strategy Board Grant
Improving minimally invasive circulating DNA diagnostic assays supports implementation of stratified and personalized intervention strategies.
Tuesday, June 17, 2014
Horizon Discovery Licenses CRISPR Gene Editing Technology
The Company announced it has entered into a non-exclusive license agreement with the Broad Institute to access intellectual property related to the CRISPR/Cas9 gene editing system.
Thursday, June 12, 2014
Horizon Completes Acquisition of CombinatoRx from Zalicus
Acquisition of revenue generating and complementary business establishes Horizon’s headquarters in North America.
Monday, June 02, 2014
Horizon to Acquire CombinatoRx Service Business and Assets from Zalicus
Horizon Discovery Group has agreed to acquire the CombinatoRx service business and related assets from Zalicus Inc for £4.7M.
Thursday, May 15, 2014
Horizon Licenses CRISPR/Cas9 Gene Editing Technology from ERS Genomics
Horizon has entered into a non-exclusive license agreement with ERS.
Saturday, May 10, 2014
Horizon, Sirion Sign Supply and Distribution Agreement
Agreement adds custom and off-the-shelf shRNA and cDNA expression capabilities to Horizon’s offering.
Monday, February 17, 2014
Horizon Discovery and Transgenomic Collaborate
Collaboration agreement aims to develop improved genetic diagnostic tests incorporating state of the art controls.
Thursday, January 16, 2014
Scientific News
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos